Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.
CalciMedica, Inc. develops calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The clinical-stage biopharmaceutical company’s lead product candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor based on zegocractin and is being studied across severe inflammatory conditions involving tissue cell injury.
Company news commonly covers financial results, clinical and preclinical updates, regulatory discussions, publications, and corporate developments. Recurring program topics include Auxora data in acute pancreatitis with systemic inflammatory response syndrome, severe COVID-19 pneumonia, and acute kidney injury, as well as preclinical work on CM5480 in pulmonary arterial hypertension.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.